|
Oneness Biotech Co., Ltd. is a biotechnology company founded in 2008 that focuses on the research and development of innovative drugs. The company’s therapeutic areas include wound care, chronic skin conditions, immune disorders, metabolic diseases, and small nucleic acid therapeutics. Its core products include FESPIXON, a cream for treating diabetic foot ulcers approved in multiple Asian markets, and Bonvadis, a wound care medical device with regulatory approvals in the United States, the European Union, and other regions. The company’s pipeline includes FB704A, an anti-IL6 monoclonal antibody for rheumatoid arthritis and tumor angiogenesis, and SNS851, a weight-loss drug targeting hepatic mitochondria for metabolic diseases. Oneness Biotech develops these candidates using its proprietary full human antibody library platform and conducts clinical trials in markets such as Australia and the United States. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Biotechnology | Homepage onenessbio.com |
| Sector Healthcare | IR page onenessbio.com/investor-relations | |
|
Tags
wound care, diabetic foot ulcers, monoclonal antibodies, metabolic diseases, rheumatoid arthritis, small nucleic acids, chronic skin conditions, obesity, liver disease, FESPIXON, Bonvadis, FB704A, SNS851
|
Press page onenessbio.com/en/news |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 18.918B |
| Market cap (USD) | $ 574.18M |
| P/E | -87.67 |
| PEG | — |
| P/BV | 1.91 |
| P/S | 135.16 |
| P/OCF | -54.74 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -9.2% |
| ROI | -10.1% |
| ROIC | -5.8% |
| Profit margin | -809.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -37.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.123M | 117.926M | 86.783M | 1.066B | 65.765M | 41.605M | 13.475M | 18.856M | 2.587M | 5.703M | 7.841M | 5.479M | 4.609M |
| Net profit | -1.045B | -1.165B | -1.313B | 359.975M | -403.303M | -241.9M | -322.206M | -235.436M | -155.446M | -14.257M | -93.017M | 199.726M | 276.253M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 55.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/S | 206.34 | — | — | — | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.







